Hasil Pencarian - N. Harbeck

  • Menampilkan 1 - 12 hasil dari 12
Perbaiki Hasil
  1. 1
    SA 8.2 Current adjuvant and neoadjuvant approaches

    SA 8.2 Current adjuvant and neoadjuvant approaches oleh N. Harbeck

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer

    Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer oleh N. Harbeck

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)

    Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR) oleh R. Bartsch, D. Lüftner, M. Balic, G. Rinnerthaler, C. Jackisch, V. Müller, M. Schmidt, N. Harbeck

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study

    Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study oleh D. Lüftner, H. Tesch, M. Schmidt, A. Hartkopf, S. Streicher, A. Resch, L. Genovese, C. Rosé, R. Valenti, N. Harbeck

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    P111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

    P111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer... oleh N. Harbeck, J.-F. Boileau, S. Modi, C. Kelly, S. Ohno, J. Wu, A. Konpa, P. Herbolsheimer, S. Safdar, Y. Zhang, L. Pusztai

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P009 A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: NERLYFE study

    P009 A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: NERLYFE study oleh N. Harbeck, A. Jegannathen, M. Schmidt, M. Tsalic, D.-T. Baerens, Y. Baschar, M. Davies, H. Abdulkhalek, M. Smakal, F. Beghdad, C. Castagné, M. Zivanov, R. Bartsch

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    P263 Patients’ perspectives on treatments for HR+/HER2– early breast cancer: developing a quantitative patient preference survey

    P263 Patients’ perspectives on treatments for HR+/HER2– early breast cancer: developing a quantitative patient preference survey oleh V. Harmer, N. Harbeck, F. Boyle, G. Werutsky, C. Ammendolea, D. El Mouzain, D.A. Marshall, C. Thomas, S. Heidenreich, H. Lu, P.-A. Dionne, M. Gao, D. Aubel, P. Pathak, M. Ryan

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy

    P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease follo... oleh A. Bardia, L. Pusztai, K. Albain, K. Kalinsky, D. Hershman, W. Barlow, E. Tokunaga, E.M. Ciruelos, D. Loirat, C. Isaacs, L. Testa, H. Dry, R. Kozarski, M. Maxwell, N. Harbeck, P. Sharma

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

    P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with e... oleh R. Bartsch, N. Harbeck, D. Wrobel, M. Zaiss, J. Terhaag, D. Guth, A. Distelrath, R. Wuerstlein, M.-O. Zahn, D. Lüftner, M. Schwitter, M. Balic, C. Jackisch, V. Müller, G. Rinnerthaler, M. Schmidt, K. Zaman, T. Schinköthe, M. Gorray, U. Breitenstein

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

    P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522... oleh S. Kümmel, P. Schmid, N. Harbeck, M. Takahashi, M. Untch, J.-F. Boileau, J. Cortes, H. McArthur, R. Dent, J. O’Shaughnessy, L. Pusztai, T. Foukakis, Y.H. Park, R. Hui, F. Cardoso, C. Denkert, Y. Zhu, W. Pan, V. Karantza, P. Fasching

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

    P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4... oleh S. Johnston, M. Toi, J. O’Shaughnessy, P. Rastogi, M. Campone, P. Neven, C.S. Huang, J. Huober, G. Garnica Jaliffe, I. Cicin, S. Tolaney, M.P. Goetz, H. Rugo, E. Senkus, L. Testa, L. Del Mastro, C. Shimizu, R. Wei, A. Shahir, M. Munoz, B. San Antonio, V. Andre, N. Harbeck, M. Martín

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients

    Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients oleh C.C. Hack, L. Häberle, S.Y. Brucker, W. Janni, B. Volz, C.R. Loehberg, A.D. Hartkopf, C.-B. Walter, G. Baake, A. Fridman, W. Malter, R. Wuerstlein, N. Harbeck, O. Hoffmann, S. Kuemmel, B. Martin, C. Thomssen, H. Graf, C. Wolf, M.P. Lux, C.M. Bayer, C. Rauh, K. Almstedt, P. Gass, F. Heindl, T. Brodkorb, L. Willer, C. Lindner, H.-C. Kolberg, P. Krabisch, M. Weigel, D. Steinfeld-Birg, A. Kohls, C. Brucker, V. Schulz, G. Fischer, V. Pelzer, B. Rack, M.W. Beckmann, T. Fehm, A. Rody, N. Maass, A. Hein, P.A. Fasching, N. Nabieva

    Diterbitkan 2020-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: